Modeling and analysis of a two-strain immuno-epidemiological model with reinfection
Nonlinear Analysis: Real World Applications, ISSN: 1468-1218, Vol: 81, Page: 104188
2025
- 2Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures2
- Readers2
- Mentions1
- News Mentions1
- News1
Most Recent News
Findings from Shanghai University Yields New Data on CDC and FDA (Modeling and Analysis of a Two-strain Immuno-epidemiological Model With Reinfection)
2025 FEB 04 (NewsRx) -- By a News Reporter-Staff News Editor at NewsRx COVID-19 Daily -- Current study results on CDC and FDA have been
Article Description
In this paper, we formulate a two-strain model with reinfection that combines immunological and epidemiological dynamics across scales, using the COVID-19 pandemic as a case study. Firstly, we conduct a qualitative analysis of both within-host and between-host models. For the within-host model, we prove the existence and stability of equilibria, and Hopf bifurcation occurs from the infection equilibrium with immune response. This implies that, under specific immune states, the virus within an infected individual may persist, and its concentration may also oscillate periodically. For the between-host model, the disease-free equilibrium always exists and is locally asymptotically stable when the epidemiological basic reproduction number ℜ0<1. In addition, the model can have boundary equilibria of strain 1 or strain 2, which are locally asymptotically stable under specific conditions. However, the co-existence equilibrium does not exist. Secondly, to explore the infection and transmission mechanisms of two strain models and obtain reliable parameter values, we utilize statistical data to fit the immuno-epidemiological model. Simultaneously, we conduct an identifiability analysis of the immuno-epidemiological model to ensure the robustness of the fitted parameters. The results demonstrate the reliable estimation of parameter ranges for structurally unidentifiable parameters with minor measurement errors using the affine invariant ensemble Markov Chain Monte Carlo algorithm (GWMCMC). Moreover, simulations illustrate that enhancing treatment of patients infected with BA.2 strains to inhibit the number of viruses released by infected cells can significantly reduce disease spread.
Bibliographic Details
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know